Sentence: Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab , trastuzumab , and docetaxel for advanced HER2-positive breast cancer .
Drug combination annotation:
[{'class': 'POS', 'spans': ['pertuzumab', 'trastuzumab', 'docetaxel'], 'is_context_needed': True}]